8.21
Schlusskurs vom Vortag:
$8.32
Offen:
$8.4
24-Stunden-Volumen:
873.43K
Relative Volume:
0.48
Marktkapitalisierung:
$1.42B
Einnahmen:
$314.85M
Nettoeinkommen (Verlust:
$12.01M
KGV:
125.34
EPS:
0.0655
Netto-Cashflow:
$47.52M
1W Leistung:
-4.53%
1M Leistung:
+6.76%
6M Leistung:
+9.32%
1J Leistung:
+63.55%
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings Inc
|
8.21 | 1.44B | 314.85M | 12.01M | 47.52M | 0.0655 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Rice Hall James & Associates LLC Acquires Shares of 251,066 Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Cash Flow - TradingKey
TradingKey - TradingKey
Xeris Biopharma Holdings Inc (XERS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xeris Biopharma Holdings Inc (XERS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xeris Biopharma Holdings, Inc. Revenue Breakdown – NASDAQ:XERS - TradingView
ETFs Investing in Xeris Biopharma Holdings, Inc. Stocks - TradingView
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Granahan Investment Management LLC - MarketBeat
XERS|Xeris Biopharma Holdings Inc|Price:8.320|Chg%:-0.090 - TradingKey
Xeris Biopharma Holdings Inc (XERS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xeris Biopharma Holdings Inc (XERS) Fundamental & Financial Data - Stocktwits
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - BioSpace
Xeris Biopharma to report Q2 2026 results on Aug 6 - scanx.trade
Press Release: Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - Moomoo
Xeris Biopharma to report Q2 results, host conference call - Bitget
XERS5927663 Bond Coupon Profile — Rate & Payments - TradingView
XERS5927663 Bond Risk Profile - TradingView
XERS5927663 Bond Profile — Key Metrics - TradingView
Xeris Biopharma Eliminates 2028 Convertible Notes Via Exchanges - TipRanks
Xeris Biopharma (Nasdaq: XERS) ends 8% 2028 notes via cash and stock - Stock Titan
Emerald Mutual Fund Advisers Trust Acquires New Shares in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Enterprise value to revenue forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS - TradingView
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last? - Yahoo Finance
Price to earnings forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS - TradingView
Form 144 XERIS BIOPHARMA HOLDINGS For: 7 July By Investing.com - Investing.com Nigeria
Insider Sell: Steven Pieper Sells 45,000 Shares of Xeris Biophar - GuruFocus
Form 4 Xeris Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock - Investing.com
Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock By Investing.com - Investing.com Nigeria
Xeris Biopharma (XERS) officer sells 45,000 shares under Rule 10b5-1 plan - Stock Titan
Steven Pieper sells 17,400 shares for $147,900 — XERS - Stock Titan
Enterprise value to EBITDA forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS - TradingView
Insider: 400-share purchase, 17,000 RSUs — XERS - Stock Titan
Xeris Biopharma Holdings Inc. (XERS) Q1 2026 Earnings: Surprise Profitability Drives 3.5% Stock Uptick - dars.gov.et
Why Xeris Biopharma (XERS) Is Up 7.7% After Governance, IP, And Balance Sheet MovesAnd What's Next - Sahm
Xeris Biopharma Holdings, Inc. (XERS) Leads with High RSI of 84 - GuruFocus
Xeris Biopharma (XERS) Surges 3.5% as Biotech Momentum BuildsPrice Action Signals - dars.gov.et
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 3, 2026 - BioSpace
Xeris Biopharma Holdings (XERS) Patent Win Puts Its Valuation Back In Focus - Sahm
XERSXeris Biopharma Holdings Inc Options - Finviz
Beth Hecht Sells 16,666 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Form 4 Xeris Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com India
Director at Xeris Biopharma (NASDAQ: XERS) receives stock and options grants - Stock Titan
Xeris Biopharma (XERS) director Nerissa Kreher listed as reporting person on Form 3 - Stock Titan
Xeris Biopharma (XERS) officer sells 90,000 shares under 10b5-1 plan - Stock Titan
Planned sale: Xeris Biopharma (XERS) officer trades 16,666 shares - Stock Titan
Insider 10b5-1 sales scheduled at XERS: 16,667 shares on 05/01 and 06/01/2026 - Stock Titan
[144] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
Xeris names CEO John Shannon as Board Chair effective July 1, 2026 - scanx.trade
Xeris Pharmaceuticals appoints new director and board chair - TipRanks
Xeris Biopharma (NASDAQ: XERS) adds Nerissa Kreher and reshapes board - Stock Titan
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xeris Biopharma Holdings Inc-Aktie (XERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pieper Steven | See Remarks |
Jul 06 '26 |
Sale |
8.50 |
17,400 |
147,900 |
1,393,653 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):